Equitec Proprietary Markets’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Equitec Proprietary Markets’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-55,100	Closed	-$7.27M	–	84
2025 Q1	$7.27M	Buy	+55,100	New	+$6.87M	5.17%	9

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Equitec Proprietary Markets's ITCI Position: Q2 2025 in Review

Equitec Proprietary Markets sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 55,100 shares — an estimated $7.27M sold.

Equitec Proprietary Markets first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $7.27M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Equitec Proprietary Markets reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Equitec Proprietary Markets sold 55,100 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $7.27M.
Equitec Proprietary Markets first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
Equitec Proprietary Markets's Intra-Cellular Therapies Inc. position peaked at $7.27M in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Equitec Proprietary Markets's 13F filing for Q2 2025, filed 6 Aug 2025.